Banned for Life From Selling Supplements, After Years of Unproven Disease Claims

Health Research Laboratories, LLC and Whole Body Supplements, LLC sold dietary supplements under names including the Ultimate Heart Formula, BG18, Black Garlic Botanicals, and Neupathic, marketing them as treatments for cardiovascular disease and diabetic nerve pain. According to a federal administrative complaint, none of those claims held up to scrutiny, and the companies had a documented history of making similarly unsubstantiated health claims.DOCUMENTED

The Federal Trade Commission finalized an order in June 2022 permanently banning the two Texas-based companies and their owner and officer, Kramer Duhon, from advertising or selling dietary supplements at all, and from making any claim that a product treats, cures, or reduces the risk of disease.DOCUMENTED

What the complaint alleges

According to the administrative complaint, Health Research Laboratories and Whole Body Supplements marketed their Ultimate Heart Formula, BG18, and Black Garlic Botanicals products with claims that they could prevent or treat cardiovascular and other diseases, while a separate product, Neupathic, was marketed as capable of curing, mitigating, or treating diabetic neuropathy — nerve damage caused by diabetes that can result in pain, numbness, and other serious complications.DOCUMENTED Samuel Levine, Director of the FTC's Bureau of Consumer Protection, said the order banning the respondents from the supplement industry “should put an end to their long history of making baseless claims that their products can treat various diseases.”DOCUMENTED

Why heart disease and neuropathy claims carry particular weight

Marketing a supplement as a treatment for cardiovascular disease or diabetic neuropathy is a categorically more serious claim than a general wellness assertion, since both conditions require ongoing, evidence-based medical management, and a consumer who believes an over-the-counter supplement is treating a serious underlying disease may delay or forgo the kind of medical care that condition actually requires.REVIEWED Diabetic neuropathy in particular can progress to serious complications, including loss of sensation that increases the risk of unnoticed injury, making a false treatment claim for that specific condition carry health consequences well beyond the financial harm of an ineffective purchase.

Why an industry-wide ban, rather than a claim-specific order

Unlike many FTC health-claims settlements, which typically prohibit specific categories of unsubstantiated claims while allowing the company to continue selling supplements under a more constrained set of marketing rules, this order took the more severe step of banning Health Research Laboratories, Whole Body Supplements, and Duhon from advertising or selling any dietary supplement whatsoever.REVIEWED That broader remedy reflects the FTC's characterization of the respondents' conduct as a pattern extending across multiple products and, according to the agency, a documented history predating this specific case — a track record the Commission apparently concluded made a narrower, claim-specific restriction insufficient to protect consumers going forward.

How the case proceeded administratively

The case moved through the FTC's administrative adjudication process rather than federal district court, with the underlying complaint filed in November 2020 and the final order approved after a proposed consent agreement roughly a year and a half later, in June 2022.DOCUMENTED That administrative track, distinct from the federal court litigation used in many other FTC consumer protection cases, allows the Commission to resolve matters through its own internal adjudicative process, though the practical effect — a binding, enforceable order — functions similarly to a federal court consent decree.REVIEWED

The respondents' Neupathic supplement was marketed to cure a condition — diabetic nerve damage — that can progress to serious, irreversible complications if the underlying disease goes unmanaged.

Why the case matters

For consumers managing chronic conditions like heart disease or diabetes, the Health Research Laboratories case is a reminder that supplement marketing claiming to treat a specific, serious medical condition warrants particular skepticism, since federal law requires this category of health claim to be backed by competent and reliable scientific evidence — a standard the FTC found these products never met despite years of marketing built directly around promising relief from exactly these two conditions.

What consumers can ask before trusting a supplement's disease claim

Before purchasing any supplement marketed to treat, cure, or reduce the risk of a specific disease, consumers can reasonably ask a company to identify the specific clinical studies supporting that claim, whether those studies were published in peer-reviewed journals, and whether they were conducted on the actual product being sold rather than on an individual ingredient in isolation.REVIEWED A company unable or unwilling to provide that information in response to a direct question is exhibiting exactly the evidentiary gap the FTC identified in this case, regardless of how confidently its marketing materials otherwise present the underlying disease claim.

Why permanent industry bans remain relatively rare

Most FTC health-claims settlements permit a company to continue selling supplements under more narrowly tailored restrictions on specific future claims, reserving a full industry ban for cases involving a demonstrated pattern of repeated violations across multiple products over an extended period.REVIEWED The FTC's characterization of Health Research Laboratories and Duhon as having a “long history” of baseless disease claims suggests the agency viewed this specific pattern of repeat conduct, rather than a single isolated marketing campaign, as the basis for concluding that a narrower remedy would not adequately protect consumers going forward. That distinction between a first-time claim and a documented pattern of repeated violations often determines whether a company faces a targeted restriction or a total industry ban.

Have documents relevant to this story? Reach us through our tips channel.